Last reviewed · How we verify
Beta-blockers including Carvedilol
Carvedilol, a beta-blocker marketed by GlaxoSmithKline, holds a significant position in the cardiovascular drug market. A key strength of Carvedilol is its broad mechanism of action, which differentiates it from other beta-blockers. The primary risk to Carvedilol's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Beta-blockers including Carvedilol |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF) (PHASE4)
- Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction (PHASE3)
- RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy (NA)
- Cardioprotection in AML (PHASE2)
- Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy (PHASE4)
- Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) (PHASE4)
- Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta-blockers including Carvedilol CI brief — competitive landscape report
- Beta-blockers including Carvedilol updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI